Key Points {#FPar1}
==========

Dual antiplatelet therapy with a P2Y~12~ inhibitor and acetylsalicylic acid is the current standard of care for patients with acute coronary syndrome; however, a residual risk of approximately 10% for recurrent ischemic events and death persists.Triple therapy with a non-vitamin K antagonist oral anticoagulant (NOAC) plus dual antiplatelet therapy reduces the risk of ischemic events, albeit at an increased risk of bleeding.Studies are now focused on dual targeting of platelet and thrombin activation pathways with a NOAC plus single antiplatelet therapy.

Introduction {#Sec1}
============

Admissions for acute coronary syndrome (ACS) in the USA accounted for \> 1.3 million unique hospitalizations in 2006, with annual costs estimated at US\$54,821 per patient \[[@CR1]\]. Rehospitalization with a cardiovascular diagnosis cost an average of US\$9510 per patient, with 30% of patients rehospitalized at least once within the first 12 months after index ACS admission. In Europe, hospital discharge rates for coronary heart disease per 100,000 population increased from 532 in 2001 to 608 in 2012 \[[@CR2]\], and the estimated annual cost (2004) per patient with ACS ranges from €7009 (UK) to €12,086 (Italy). The largest contributor to total costs was hospital stay \[[@CR3]\].

Despite optimal standard care and secondary prevention, patients remain at high risk of further ischemic coronary events and death in the months and years after an index ACS event \[[@CR4], [@CR5]\]. This article examines a 'dual antiplatelet' approach for secondary prevention in patients with ACS and explores the evidence base for a 'dual strategy' approach in this setting.

Antithrombotic Approaches to Secondary Prevention {#Sec2}
=================================================

Thrombus formation after atherosclerotic plaque rupture involves both platelet activation and fibrin generation (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6], [@CR7]\]. Furthermore, elevated thrombin generation persists long after the index ACS event \[[@CR8]\], supporting long-term risk-reduction strategies \[[@CR5]\]. Platelet activation and coagulation are highly interdependent processes. Thrombin is central to both, by stimulating platelet activation and aggregation and catalyzing fibrinogen conversion to fibrin, stabilizing the thrombus \[[@CR9], [@CR10]\]. This interdependency supports a 'dual pathway' strategy targeting the coagulation cascade and the platelet component of thrombus formation.Fig. 1Current concepts of the coagulation process (reproduced with permission from De Caterina et al. \[[@CR6]\]). *ADP* adenosine diphosphate, *GP* glycoprotein, *PAR* protein-activated receptor, *TF* tissue factor, *vWF* von Willebrand factor

Historical data confirm the efficacy of targeting the dual pathway in reducing ischemic events after ACS \[[@CR11]\]. Meta-analysis data show that, versus acetylsalicylic acid (ASA) alone, ASA plus warfarin significantly reduced the risk of death, myocardial infarction (MI), or stroke in patients with an international normalized ratio of 2--3 (*p* \< 0.0001). However, major bleeding risk was increased \[[@CR11]\] and led to the restriction of combined anticoagulant and antiplatelet therapy to patients with ACS and a firm indication for oral anticoagulation, such as paroxysmal, persistent, or permanent atrial fibrillation (AF), and a CHA~2~DS~2~--VASc (Cardiac failure, Hypertension, Age ≥ 75 \[2 points\], Diabetes, Stroke \[2 points\]--Vascular disease, Age 65--74, Sex category) score ≥ 2 \[[@CR12]\]. The long-term standard of care for antithrombotic treatment after ACS remains 'dual antiplatelet therapy' with potent P2Y~12~ inhibitors (clopidogrel, prasugrel, and ticagrelor) plus ASA \[[@CR12], [@CR13]\], based on trial data showing clinical benefit when added to ASA.

The first trial demonstrating clinical benefit was the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, where addition of clopidogrel to various doses of ASA reduced the rate of cardiovascular death, MI, or stroke versus ASA alone. As might be expected, bleeding risk increased with increasing ASA dose \[[@CR14]\].

Subsequent trials have demonstrated the superiority of prasugrel and ticagrelor over clopidogrel in reducing ischemic events, albeit with increased bleeding. The TRITON--TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel--Thrombolysis In Myocardial Infarction 38) trial of \> 13,000 patients with ACS undergoing percutaneous coronary intervention (PCI) compared prasugrel and ASA with clopidogrel and ASA. The composite of cardiovascular death, non-fatal MI, or non-fatal stroke occurred in 9.9% of patients receiving prasugrel and in 12.1% receiving clopidogrel (*p* \< 0.001). Non-coronary artery bypass graft (CABG)-related Thrombosis in MI (TIMI) major bleeding was more frequent with prasugrel (2.4% vs. 1.8%, respectively; *p* = 0.03), as was fatal bleeding \[[@CR15]\].

Vascular death, MI, or stroke occurred in 9.8% of \> 18,000 patients with ACS in the PLATO (PLATelet inhibition and patient Outcome) trial administered ticagrelor plus ASA versus 11.7% treated with clopidogrel plus ASA (*p* \< 0.001). Major bleeding rates between the groups were similar. However, non-CABG-related TIMI major bleeding was more frequent with ticagrelor (2.8% vs. 2.2%, respectively; *p* = 0.03), as was fatal intracranial bleeding \[[@CR16]\].

These studies established the role of P2Y~12~ inhibitors as the mainstay of antithrombotic therapy in ACS. However, although TRITON--TIMI 38 and PLATO showed superiority over clopidogrel in reducing post-ACS ischemic events, they revealed a residual risk of recurrent cardiovascular events and death of \~ 10% despite 'optimal' dual antiplatelet therapy \[[@CR17]\]. Therefore, new approaches to further reduce the residual risk of subsequent ischemic events, while minimizing bleeding risk, are required.

More recently, studies have explored novel therapeutic agents targeting different pathways of the coagulation cascade and adding a new agent to a dual antiplatelet regimen.

Vorapaxar, a protease-activated receptor-1 antagonist, inhibits thrombin-induced platelet aggregation. In the phase III TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, 12,944 patients with ACS received vorapaxar or placebo plus standard antiplatelet therapy, predominantly clopidogrel plus ASA \[[@CR18]\]. Vorapaxar increased moderate or severe bleeding (7.2% vs. 5.2%; *p* \< 0.001) and intracranial bleeding (1.1% vs. 0.2%; *p* \< 0.001) in GUSTO (Global Utilization of Streptokinase and t-PA \[tissue plasminogen activator\] for Occluded Coronary Arteries), without improving ischemic outcomes. The composite of cardiovascular death, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization was not significantly reduced with vorapaxar (18.5% vs. 19.9%; *p* = 0.07) \[[@CR18]\].

Several non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), including apixaban, darexaban, letaxaban, and rivaroxaban (direct Factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor), have been evaluated in post-ACS, secondary prevention trials. The APPRAISE-2 (Apixaban for Prevention of Acute Ischaemic Events-2) \[[@CR19]\], RUBY-1 \[[@CR20]\], AXIOM-ACS \[[@CR21]\], ATLAS ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome--Thrombolysis in Myocardial Infarction 51) \[[@CR22]\], and RE-DEEM \[[@CR23]\] trials tested these agents in combination with dual antiplatelet therapy (Table [1](#Tab1){ref-type="table"}).Table 1Endpoints of the ATLAS ACS 2 TIMI 51, APPRAISE-2, RE-DEEM, RUBY-1, and AXIOM-ACS trialsTrialIschemic eventsBleeding eventsATLAS ACS 2 TIMI 51 \[[@CR22]\]CV death, MI, or stroke: 9.1% with rivaroxaban 2.5 mg bid vs. 10.7% with placebo (*p* = 0.02)^a^Non-CABG-related bleeding: 1.8% with rivaroxaban 2.5 mg bid vs. 0.6% with placebo (*p* \< 0.001)^a^Intracranial hemorrhage: 0.4% with rivaroxaban 2.5 mg bid vs. 0.2% with placebo (*p* = 0.04)^a^APPRAISE-2 \[[@CR19]\]CV death, MI, or ischemic stroke: 7.5% with apixaban vs. 7.9% with placebo (*p* = NS)Major bleeding: 1.3% with apixaban vs. 0.5% with placebo (*p* = 0.001)RE-DEEM \[[@CR23]\]CV death, non-fatal MI, or non-hemorrhagic stroke: 4.6, 4.9, 3.0, and 3.5% with dabigatran 50, 75, 110, and 150 mg bid, respectively, vs. 3.8% with placeboMajor or clinically relevant minor bleeding: 3.5, 4.3, 7.9, and 7.8% with dabigatran 50, 75, 110, and 150 mg bid, respectively, vs. 2.2% with placebo (*p* \< 0.001 for dabigatran 110 and 150 mg bid vs. placebo)^a^RUBY-1 \[[@CR20]\]All-cause death, non-fatal MI, non-fatal stroke, or severe recurrent ischemia: 6.5% with darexaban vs. 5.2% with placebo^a^Major or clinically relevant non-major bleeding: 5.6--7.3% (od) and 6.8--11.3% (bid) with darexaban 10--60 mg/day vs. 3.1% with placebo (overall *p* = 0.02)^a^AXIOM-ACS \[[@CR21]\]CV death, non-fatal MI, non-fatal stroke, or myocardial ischemia requiring hospitalization: 4.8% with letaxaban 20--240 mg/day vs. 4.4% with placebo (*p* = NS)TIMI major bleeding: 0.9% with letaxaban 20--240 mg/day vs. 0.5% with placebo (*p* = NS)*bid* twice daily, *CABG* coronary artery bypass grafting, *CV* cardiovascular, *MI* myocardial infarction, *NS* not significant, *od* once daily, *TIMI* thrombolysis in myocardial infarction^a^Kaplan--Meier estimates

The phase III ATLAS ACS 2 TIMI 51 trial \[[@CR22]\] randomized over 15,500 patients with ACS to receive rivaroxaban 2.5 or 5 mg twice daily (doses based on phase II ATLAS ACS TIMI 46 trial \[[@CR24]\]) or placebo in addition to ASA with or without clopidogrel or ticlopidine in accordance with local guidelines. The findings led to approval of rivaroxaban in Europe in combination with ASA alone or ASA and clopidogrel (or ticlopidine) in selected patients with ACS at low risk of bleeding; rivaroxaban remains the only NOAC currently approved for this indication \[[@CR12]\].

In contrast, other trials \[[@CR19]--[@CR21], [@CR23]\] with NOACs in a triple therapy regimen failed to show net clinical benefit. The phase III APPRAISE-2 trial aimed to investigate the efficacy and safety of apixaban in addition to standard antiplatelet therapy in patients with a recent ACS and at least two additional risk factors for ischemic events. The trial was terminated early because apixaban 5 mg twice daily plus antiplatelet therapy led to an increase in the number of major bleeding events in this patient population, without a significant reduction in recurrent ischemic events \[[@CR19]\]. These NOAC trials demonstrate the need for 'optimal balance' between reducing ischemic events and increasing bleeding risk when combining anticoagulant and antiplatelet therapies in patients with ACS.

The phase II GEMINI-ACS-1 trial took a different approach to secondary prevention and compared rivaroxaban 2.5 mg twice daily plus a P2Y~12~ inhibitor with ASA plus a P2Y~12~ inhibitor in patients with ACS \[[@CR25]\]. The risk of TIMI non-CABG clinically significant bleeding was similar in both trial arms. The rate of the exploratory endpoint of the composite of cardiovascular death, MI, stroke, or definite stent thrombosis was also similar between the treatment arms.

The role of ASA has been questioned because of concerns over increased bleeding with triple therapy. WOEST (What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing), a small-scale, open-label study \[[@CR26]\], compared clopidogrel alone (dual therapy) with clopidogrel plus ASA (triple therapy) in patients already receiving long-term oral anticoagulation who had undergone PCI \[[@CR26]\]. Compared with triple therapy, dual therapy had a lower rate of any bleeding (19.4% vs. 44.4%; *p* \< 0.0001) and a lower rate of death, MI, stroke, target vessel revascularization, or stent thrombosis (11.1% vs. 17.6%; *p* = 0.025) \[[@CR26]\]. A large meta-analysis was conducted to compare the safety and efficacy of dual therapy with triple therapy in patients on oral anticoagulants undergoing PCI, and obtained similar findings to the WOEST study; there was an increased risk of major bleeding events with triple therapy compared with dual therapy \[[@CR27]\]. The WOEST 2 registry (ClinicalTrials.gov identifier NCT02635230) plans to recruit 2200 patients with AF undergoing coronary revascularization, treated with an oral anticoagulant and a P2Y~12~ inhibitor with or without ASA, with completion scheduled for 2019. Despite its limitations, WOEST was the first study to suggest that combining an anticoagulant with a P2Y~12~ inhibitor alone may be suitable for long-term secondary prevention after an ACS event in patients with no prior indication for long-term anticoagulant therapy such as AF.

In the PIONEER AF-PCI (Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI) trial \[[@CR28]\] of patients with AF undergoing PCI, over 50% of patients had a history of ACS in the preceding 12 months (Fig. [2](#Fig2){ref-type="fig"}). This study confirmed the safety, in terms of reduced TIMI major and minor bleeding, of rivaroxaban 2.5 mg twice daily with dual antiplatelet therapy and rivaroxaban 15 mg once daily with single antiplatelet therapy versus warfarin plus dual antiplatelet therapy. The trial was not powered to show superiority or non-inferiority for the reduction in major adverse cardiovascular events. Following the PIONEER AF-PCI trial, up to 12 months' treatment with rivaroxaban 15 mg once daily (or 10 mg once daily in patients with moderate renal impairment) plus a P2Y~12~ inhibitor was approved by the European Medicines Agency for use in patients with non-valvular AF who undergo PCI with stent placement; however, the approval document highlighted that data in this population were limited and no data were available in such patients with a history of stroke or transient ischemic attack \[[@CR29]\].Fig. 2Design of the PIONEER AF-PCI trial \[[@CR42]\]. ^a^Creatinine clearance 30--49 mL/min: 10 mg od. ^b^First dose 72--96 h after sheath removal. ^c^ASA (75--100 mg/day) plus clopidogrel (75 mg/day) (alternative use of prasugrel or ticagrelor allowed, but capped at 15%). ^d^First dose 12--72 h after sheath removal. *ASA* acetylsalicylic acid, *bid* twice daily, *DAPT* dual antiplatelet therapy, *INR* international normalized ratio, *NVAF* non-valvular atrial fibrillation, *od* once daily, *PCI* percutaneous coronary intervention,*R* randomization, *VKA* vitamin K antagonist

Similarly, the RE-DUAL PCI (Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation) trial compared two dabigatran-based (110 or 150 mg twice daily) dual antithrombotic therapy regimens with warfarin-based triple therapy in patients with AF after PCI (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR30]\]. Dabigatran plus a P2Y~12~ inhibitor was associated with a significantly lower rate of major or clinically relevant non-major bleeding than warfarin plus a P2Y~12~ inhibitor plus ASA. The trial also found that when data from both dabigatran arms were pooled, the dual-therapy regimens were non-inferior to the triple-therapy regimen in terms of efficacy.Fig. 3Design of the RE-DUAL PCI trial \[[@CR30]\]. Non-US patients aged ≥ 80 years and Japanese patients aged ≥ 70 years were randomized to receive dabigatran 110 mg bid dual therapy or warfarin-based triple therapy in accordance with the respective product labels in these countries. ^a^First dose within 120 h after PCI. ^b^Clopidogrel (75 mg od) or ticagrelor (90 mg bid) for at least 12 months after randomization. ^c^ASA ≤ 100 mg od was stopped at 1 or 3 months in patients who received bare-metal stent or drug-eluting stent implantation, respectively. *ASA* acetylsalicylic acid, *bid* twice daily, *INR* international normalized ratio, *NVAF* non-valvular atrial fibrillation, *od* once daily, *PCI* percutaneous coronary intervention, *R* randomization

European guidance supports triple therapy for the shortest time possible for patients with ACS and AF undergoing PCI \[[@CR12], [@CR31]\]. Furthermore, European guidelines on the use of dual antiplatelet therapy in coronary artery disease state that dual therapy with clopidogrel and an oral anticoagulant should be considered in place of triple therapy when a patient with an indication for anticoagulation has a bleeding risk that outweighs their ischemic risk \[[@CR31]\]. However, these recommendations are based partly on expert opinion, because prospective studies of triple therapy in these patients are limited, although further trials are currently recruiting (Table [2](#Tab2){ref-type="table"}).Table 2Ongoing trials in patients with atrial fibrillation undergoing percutaneous coronary interventionTrial detailsAUGUSTUSENTRUST AF-PCIClinicalTrials.gov identifierNCT02415400NCT02866175Study phaseIVIIIPatient populationAF + ACS or PCI with stentingAF + PCI with stentingInterventionsApixaban 2.5 or 5 mg bid + P2Y~12~ inhibitor ± ASAEdoxaban 60 mg (or 30 mg) od + P2Y~12~ inhibitorVKA + P2Y~12~ inhibitor ± ASAVKA + P2Y~12~ inhibitor + ASA^a^Primary endpointMajor or CRNM bleedingMajor or CRNM bleedingSecondary endpointsDeath, ischemic eventsDeath, ischemic eventsTarget enrollment (*n*)46001500Expected completionDecember 2018November 2018*ACS* acute coronary syndrome, *AF* atrial fibrillation, *ASA* acetylsalicylic acid, *bid* twice daily, *CRNM* clinically relevant non-major, *od* once daily, *PCI* percutaneous coronary intervention, *VKA* vitamin K antagonist^a^ASA for 1--12 months guided by clinical presentation

Discussion and Future Perspectives {#Sec3}
==================================

The development of NOACs, which have demonstrated fewer intracranial bleeding events and deaths than VKAs in AF trials \[[@CR32]\], has renewed interest in a dual pathway strategy for the secondary prevention of ACS, targeting both the coagulation cascade and the platelet component of thrombus formation \[[@CR7], [@CR33]\].

The disparate outcomes of the only two phase III trials (ATLAS ACS 2 TIMI 51 and APPRAISE-2) conducted to date in patients with ACS deserve further discussion. The apixaban dose in APPRAISE-2 was the same as that recommended for use in patients with AF, whereas the rivaroxaban dose in ATLAS ACS 2 TIMI 51 was adjusted to 25--50% of the AF dose \[[@CR22]\]. The lower rivaroxaban dose (2.5 mg twice daily) exhibited the best efficacy and safety profile \[[@CR22]\].

The importance of dose selection for patients with ACS may be partly explained by the 'dual property' of thrombin. Thrombin is anticoagulatory at low concentrations but a procoagulant at high concentrations, a scenario known as the 'thrombin paradox' \[[@CR34]\]. The GUSTO IIb trial of patients with ACS showed elevated thrombin generation in the 12 months post index event \[[@CR8]\]. However, the correlation between thrombin generation and clinical events was non-linear, with higher rates of cardiac death or MI seen at both very low and very high thrombin levels, complicating the search for an optimal post-ACS anticoagulant dose \[[@CR34]\].

In addition, compared with ATLAS ACS 2 TIMI 51, APPRAISE-2 patients were older and more likely to have diabetes mellitus and/or renal dysfunction, and non-ST-elevation MI versus ST-elevation MI as their index event \[[@CR19], [@CR22], [@CR33]\]. Furthermore, ATLAS ACS 2 TIMI 51 excluded patients with prior stroke or transient ischemic attack who were already receiving ASA plus a P2Y~12~ inhibitor \[[@CR22], [@CR33]\]. The higher-risk population of APPRAISE-2 may have been less responsive to anticoagulant therapy than the ATLAS ACS 2 TIMI 51 population \[[@CR22], [@CR33]\].

The benefit--risk profile of dabigatran in patients with ACS can only be determined in an adequately powered phase III trial. To date, no such trial has been scheduled; however, the two highest dabigatran doses used in the phase II RE-DEEM trial significantly increased major and clinically relevant minor bleeding, and were identical to those used in patients with AF \[[@CR23], [@CR33]\].

The recently completed PIONEER AF-PCI \[[@CR28]\] and RE-DUAL PCI \[[@CR35]\] trials and the ongoing AUGUSTUS (NCT02415400) and ENTRUST AF-PCI (NCT02866175) trials should help to determine the treatment regimens with the optimal benefit--risk profile in patients with ACS and AF. The trials will also provide additional information on the appropriate duration of antiplatelet therapy and intensity of oral anticoagulation in patients with ACS and AF \[[@CR28]\], and on the feasibility of removing ASA from the treatment regimen \[[@CR33]\].

Most patients with ACS have co-morbidities and risk factors that put them at increased risk of ischemic or bleeding events \[[@CR36]\]. Therefore, individualized assessment of bleeding risk and risk of coronary stent thrombosis are important considerations in guiding the duration of triple therapy \[[@CR12], [@CR31], [@CR37], [@CR38]\] and stent type in patients requiring PCI.

Renal impairment occurs in approximately 30--40% of patients with ACS and is an independent predictor of increased mortality and major bleeding \[[@CR36]\]. Although the same antiplatelet regimens are recommended regardless of renal function status, dose adjustments of oral anticoagulants are usually recommended for those with moderate renal impairment \[[@CR12], [@CR37]\]. Dabigatran is unlikely to be the first-choice NOAC in patients with moderate renal impairment because it is primarily excreted via the kidneys \[[@CR37]\]. Minimal data are available in patients with severe renal impairment, and no prospective data exist for patients with end-stage renal disease or who are on hemodialysis \[[@CR37]\].

Diabetes is present in 20--30% of patients with ACS and is an independent predictor of mortality \[[@CR12], [@CR36]\]. Although guidelines recommend that patients with diabetes receive the same antithrombotic regimens as those without diabetes \[[@CR12]\], treatment of this patient population remains suboptimal \[[@CR36]\]. In a subanalysis, TRITON--TIMI 38, patients with diabetes received a greater net clinical benefit from prasugrel versus clopidogrel than non-diabetic patients \[[@CR39]\]. However, no such interaction with diabetic status was found in the PLATO trial with ticagrelor \[[@CR40]\] or ATLAS ACS 2 TIMI 51 with rivaroxaban \[[@CR22]\].

Female sex is a predictor of major bleeding in ACS, and women have an increased risk of recurrence of ischemic events at 6 months \[[@CR36]\]. Current guidelines recommend that men and women with ACS are managed similarly; however, some studies have suggested that women are less likely to receive evidence-based care \[[@CR12]\].

Patients aged ≥ 75 years with ACS have an increased risk of recurrent ischemic events, bleeding, and mortality, with 60% of all ACS-related deaths occurring in this age group \[[@CR41]\]. However, again, they are less likely to receive evidence-based therapies \[[@CR12]\]. Although prasugrel is generally not recommended in elderly patients after TRITON--TIMI 38 did not find a net clinical benefit in this age group \[[@CR15]\], the PLATO trial \[[@CR41]\] did not find significant differences in efficacy and safety in elderly patients receiving ticagrelor. Guidelines recommend that close attention be paid to specific contraindications in elderly patients, as well as renal function. Individualized benefit--risk assessments in this age group should take account of estimated life expectancy, co-morbidities, quality of life, and patient preferences \[[@CR12]\].

Conclusion {#Sec4}
==========

Despite optimal secondary prevention after ACS, a residual ongoing risk of recurrent ischemic events remains up to and beyond 12 months. Trials of triple therapy (oral anticoagulant plus dual antiplatelet therapy) targeting the dual pathway have shown reduced ischemic events, albeit at an increased risk of bleeding. Ongoing studies are focusing on dual therapy (oral anticoagulant plus single antiplatelet therapy) to target the platelet- and fibrin-mediated pathways of thrombus formation for ACS secondary prevention. Several trials are underway, particularly in patients with concomitant AF, and will provide important data on the optimal intensity of oral anticoagulation, the optimal antiplatelet therapy regimen, the use of oral anticoagulation combined with new P2Y~12~ inhibitors, and the efficacy and safety of NOACs versus VKAs. Many patients with ACS have co-morbidities, which require consideration to enable optimal treatment and long-term outcomes. The addition of anticoagulation may enable an individualized approach to the use of antithrombotic agents for secondary prevention of ACS. Algorithms to simplify choice between the increased treatment options may help clinicians assess benefits and risks of each treatment strategy and balance the risk of thrombotic events with the risk of bleeding \[[@CR36]\].
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